The largest database of trusted experimental protocols

Acquity uplc ms tqd system

Manufactured by Waters Corporation

The ACQUITY UPLC/MS TQD system is a high-performance liquid chromatography and tandem mass spectrometry instrument designed for analytical applications. It provides rapid separation, detection, and quantification of chemical compounds with high sensitivity and resolution.

Automatically generated - may contain errors

Lab products found in correlation

12 protocols using acquity uplc ms tqd system

1

Compound Stability Assessment in Rat Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols
Compounds were diluted in rat plasma added with 10 % DMSO to help solubilization. Plasma was already pre-heated at 37° C (30 min). The final compound concentration was 1.0 μM. At time points (immediately after dilution, 30, 60, 120, 240, 360 and 420 min) a 40 µL aliquot of the incubation solution was diluted in 150 µL of cold CH3CN spiked with 200 nM warfarin as internal standard. After vortexing for 30 s, the solution was centrifuged at 3500 g for 15 min at 4 °C and the supernatant transferred for LC-MS analysis on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) Mass Spectrometer equipped with an Electrospray Ionization interface. Briefly, 3.0 µL of the supernatant were injected on a reversed phase column (BEH C18 1.7 µm 2.1X50 mm) and separated with a linear acetonitrile gradient. Compounds were quantified on the basis of their MRM (Multiple Reaction Monitoring) peak areas. The response factors, calculated on the basis of the internal standard peak area, were then plotted over time. For each compound, analyses were conducted in triplicate: compound remaining (%) with corresponding standard deviation at 420 minutes is reported.
+ Open protocol
+ Expand
2

In Vitro Microsomal Metabolic Stability

Check if the same lab product or an alternative is used in the 5 most similar protocols
Freshly prepared
10 mM MeCN stock solution of test compound was preincubated at 37
°C for 15 min with mouse liver microsomes added in 0.1 M Tris
HCl buffer (pH 7.4). The final concentration was 4.6 μM. After
preincubation, the cofactors (NADPH, G6P, G6PDH, and MgCl2 predissolved in 0.1 M Tris HCl) were added to the incubation mixture,
and the incubation was continued at 37 °C for 1 h. At each time
point (0, 5, 15, 30, and 60 min), 30 μL of incubation mixture
was diluted with 200 μL of cold MeCN spiked with 200 nM internal
standard followed by centrifugation at 3300 × g for 15 min. The supernatant was further diluted with H2O (1:1) for analysis. The concentration of the test compound was
quantified by LC/MS/MS on a Waters ACQUITY UPLC/MS TQD system consisting
of a TQD MS equipped with an ESI interface. The analyses were run
on an ACQUITY UPLC BEH C18 (50 × 2.1 mm ID, particle size 1.7
μm) with a VanGuard BEH C18 precolumn (5 × 2.1 mm ID, particle
size 1.7 μm) at 40 °C. For each compound, the appropriate
mobile phase was chosen. ESI was applied in positive mode. The percentage
of test compound remaining at each time point relative to t = 0 was calculated. t1/2 was
determined by a one-phase decay equation using a nonlinear regression
of compound concentration vs time. Values are the mean of at least
two independent experiments performed in two technical replicates.
+ Open protocol
+ Expand
3

In Vitro Hepatic Metabolic Stability

Check if the same lab product or an alternative is used in the 5 most similar protocols
10 mM DMSO stock solution of each compound was pre-incubated at 37°C for 15 min with liver microsomes from all the three species (mouse, rat, human) in 0.1M Tris-HCl buffer (pH 7.4). The final concentration was 4.6 μM. After pre-incubation, the co-factors (NADPH, G6P, G6PDH and MgCl2 pre-dissolved in 0.1M Tris-HCl) were added to the mixture and the incubation was continued at 37°C for 1 h. At each time point (0, 5, 15, 30, 60 min), 30 μL of mixture was diluted with 200 μL cold CH3CN spiked with 200 nM of internal standard, followed by centrifugation at 3500 g for 15 min. The supernatant was then further diluted with H2O (1:1) for analysis. The concentration of each compound was quantified by LC/MS-MS on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) Mass Spectrometer equipped with an Electrospray Ionization interface. The analyses were run on an ACQUITY UPLC BEH C18 (50 × 2.1mm ID, particle size 1.7 mm) with a VanGuard BEH C18 pre-column (5 × 2.1mm ID, particle size 1.7 μm) at 40°C, using 0.1% HCOOH in H2O (A) and 0.1% HCOOH in CH3CN (B) as mobile phases. The percentage of test compound remaining at each time point relative to the amount observed at t = 0 was calculated. The half-lives (t½) were determined by a one-phase decay equation using a non-linear regression of compound concentration versus time.
+ Open protocol
+ Expand
4

Plasma Stability Assay for Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
Compounds were diluted in mouse plasma added with 5% DMSO to help solubilization. Plasma was already pre-heated at 37° C (10 min). The final compound concentration was 2 μM. At time points (immediately after dilution, 5, 15, 30, 60, 120, min) a 40 μL aliquot of the incubation solution was diluted in 120 μL of cold CH3CN spiked with Warfarin 200 nM, as internal standard. After 30 sec of vortexing, the solution was centrifuged at 3500g for 15 min at 4°C and the surnatant transferred for LC-MS analysis on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) Mass Spectrometer equipped with an Electrospray Ionization interface. Briefly: 3 μL of the surnatant were injected on a reversed phase column (BEH C18 2.1X50 mm) and separated with a linear acetonitrile gradient. Compounds were quantified on the basis of their MRM (Multiple Reaction Monitoring) peak areas. The response factors, calculated on the basis of the internal standard peak area, were then plotted over time. When possible, response vs time profiles were fitted with Prism (GraphPad Software, Inc., USA) to estimate compound half lives in plasma.
+ Open protocol
+ Expand
5

Plasma Stability Determination of Test Compound

Check if the same lab product or an alternative is used in the 5 most similar protocols
Freshly prepared 10
mM MeCN stock solution of test compound was diluted 50-fold with DMSO/H2O (1:1) and incubated at 37 °C for 2 h with mouse plasma
added in 5% DMSO (preheated at 37 °C for 10 min). The final concentration
was 2 μM. At each time point (0, 5, 15, 30, 60, and 120 min),
50 μL of incubation mixture was diluted with 200 μL of
cold MeCN spiked with 200 nM internal standard followed by centrifugation
at 3300 × g for 20 min. The supernatant was
further diluted with H2O (1:1) for analysis. The concentration
of test compound was quantified by LC/MS/MS on a Waters ACQUITY UPLC/MS
TQD system consisting of a TQD MS equipped with an ESI interface.
The analyses were run on an ACQUITY UPLC BEH C18 (50 × 2.1 mm
ID, particle size 1.7 μm) with a VanGuard BEH C18 precolumn
(5 × 2.1 mm ID, particle size 1.7 μm) at 40 °C. For
each compound, the appropriate mobile phase was chosen. ESI was applied
in positive mode. The response factors, calculated on the basis of
the internal standard peak area, were plotted over time. When possible,
response vs time profiles were fitted with Prism (GraphPad Software,
Inc., USA) to estimate compound t1/2 in
plasma. Values are the mean of at least two independent experiments
performed in two technical replicates.
+ Open protocol
+ Expand
6

Metabolic Stability Assay of Test Compound

Check if the same lab product or an alternative is used in the 5 most similar protocols
10 mM DMSO stock solution of test compound was diluted 50-fold with DMSO-H2O (1:1) and incubated at 37°C for 2 h with mouse plasma added 5% DMSO (pre-heated at 37°C for 10 min). The final concentration was 2 μM. At each time point (0, 5, 15, 30, 60, 120 min), 50 μL of incubation mixture was diluted with 200 μL cold CH3CN spiked with 200 nM of internal standard, followed by centrifugation at 3.750 rpm for 20 min. The supernatant was further diluted with H2O (1:1) for analysis. The concentration of test compound was quantified by LC/MS-MS on a Waters ACQUITY UPLC/MS TQD system consisting of a Triple Quadrupole Detector (TQD) Mass Spectrometer (MS) equipped with an Electrospray Ionization (ESI) interface. The analyses were run on an ACQUITY UPLC BEH C18 column (50 × 2.1 mmID, particle size 1.7 μm) with a VanGuard BEH C18 pre-column (5 × 2.1 mmID, particle size 1.7μm) at 40°C, using H2O + 0.1% HCOOH in H2O (A) and CH3CN + 0.1% HCOOH (B) as mobile phase. ESI was applied in positive mode. The response factors, calculated on the basis of the internal standard peak area, were plotted over time. Response factor versus time profiles were fitted with Prism (GraphPad Software, Inc., USA) to estimate compounds half-life (t½) in mouse plasma.
+ Open protocol
+ Expand
7

In Vitro Hepatic Metabolic Stability

Check if the same lab product or an alternative is used in the 5 most similar protocols
10 mM DMSO stock solution of each compound was pre-incubated at 37°C for 15 min with liver microsomes from all the three species (mouse, rat, human) in 0.1M Tris-HCl buffer (pH 7.4). The final concentration was 4.6 μM. After pre-incubation, the co-factors (NADPH, G6P, G6PDH and MgCl2 pre-dissolved in 0.1M Tris-HCl) were added to the mixture and the incubation was continued at 37°C for 1 h. At each time point (0, 5, 15, 30, 60 min), 30 μL of mixture was diluted with 200 μL cold CH3CN spiked with 200 nM of internal standard, followed by centrifugation at 3500 g for 15 min. The supernatant was then further diluted with H2O (1:1) for analysis. The concentration of each compound was quantified by LC/MS-MS on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) Mass Spectrometer equipped with an Electrospray Ionization interface. The analyses were run on an ACQUITY UPLC BEH C18 (50 × 2.1mm ID, particle size 1.7 mm) with a VanGuard BEH C18 pre-column (5 × 2.1mm ID, particle size 1.7 μm) at 40°C, using 0.1% HCOOH in H2O (A) and 0.1% HCOOH in CH3CN (B) as mobile phases. The percentage of test compound remaining at each time point relative to the amount observed at t = 0 was calculated. The half-lives (t½) were determined by a one-phase decay equation using a non-linear regression of compound concentration versus time.
+ Open protocol
+ Expand
8

Microsomal Stability Assay for Compound

Check if the same lab product or an alternative is used in the 5 most similar protocols
10 mM DMSO stock solution of test compound was pre-incubated at 37 °C for 15 min with mouse liver microsomes added 0.1 M Tris–HCl buffer (pH 7.4). The final concentration was 4.6 µM. After pre-incubation, the co-factors (NADPH, G6P, G6PDH and MgCl2 pre-dissolved in 0.1 M Tris–HCl) were added to the incubation mixture and the incubation was continued at 37 °C for 1 h. At each time point (0, 5, 15, 30, 60 min), 30 µL of incubation mixture was diluted with 200 µL cold CH3CN spiked with 200 nM of internal standard, followed by centrifugation at 3500 g for 15 min. The supernatant was further diluted with H2O (1:1) for analysis. The concentration of test compound was quantified by LC/MS–MS on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) Mass Spectrometer equipped with an Electrospray Ionization interface. The analyses were run on an ACQUITY UPLC BEH C18 (50 × 2.1mmID, particle size 1.7 µm) with a VanGuard BEH C18 pre-column (5 × 2.1mmID, particle size 1.7 µm) at 40 °C, using 0.1% HCOOH in H2O (A) and 0.1% HCOOH in CH3CN (B) as mobile phase. Electrospray ionization (ESI) was applied in positive mode. The percentage of test compound remaining at each time point relative to t = 0 was calculated. The half-lives (t½) were determined by an one-phase decay equation using a non-linear regression of compound concentration versus time.
+ Open protocol
+ Expand
9

Plasma Stability Assay of Test Compound

Check if the same lab product or an alternative is used in the 5 most similar protocols
10 mM DMSO stock solution of test compound was diluted 50-fold with DMSO-H2O (1:1) and incubated at 37 °C for 2 h with mouse plasma added 5% DMSO (pre-heated at 37 °C for 10 min). The final concentration was 2 µM. At each time point (0, 5, 15, 30, 60, 120 min), 50 µL of incubation mixture was diluted with 200 µL cold CH3CN spiked with 200 nM of internal standard, followed by centrifugation at 3500 g for 20 min. The supernatant was further diluted with H2O (1:1) for analysis. The concentration of test compound was quantified by LC/MS–MS on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) Mass Spectrometer equipped with an Electrospray Ionization interface. The analyses were run on an ACQUITY UPLC BEH C18 (50 × 2.1mmID, particle size 1.7 µm) with a VanGuard BEH C18 precolumn (5 × 2.1mmID, particle size 1.7 µm) at 40 °C, using 0.1% HCOOH in H2O (A) and 0.1% HCOOH in CH3CN (B) as mobile phase. Electrospray ionization (ESI) was applied in positive mode. The response factors, calculated on the basis of the internal standard peak area, were plotted over time. When possible, response vs. time profiles were fitted with Prism (GraphPad Software, Inc., USA) to estimate compounds half-life in plasma.
+ Open protocol
+ Expand
10

Metabolic Stability Assay of Test Compound

Check if the same lab product or an alternative is used in the 5 most similar protocols
10 mM DMSO stock solution of test compound was diluted 50-fold with DMSO-H2O (1:1) and incubated at 37°C for 2 h with mouse plasma added 5% DMSO (pre-heated at 37°C for 10 min). The final concentration was 2 μM. At each time point (0, 5, 15, 30, 60, 120 min), 50 μL of incubation mixture was diluted with 200 μL cold CH3CN spiked with 200 nM of internal standard, followed by centrifugation at 3.750 rpm for 20 min. The supernatant was further diluted with H2O (1:1) for analysis. The concentration of test compound was quantified by LC/MS-MS on a Waters ACQUITY UPLC/MS TQD system consisting of a Triple Quadrupole Detector (TQD) Mass Spectrometer (MS) equipped with an Electrospray Ionization (ESI) interface. The analyses were run on an ACQUITY UPLC BEH C18 column (50 × 2.1 mmID, particle size 1.7 μm) with a VanGuard BEH C18 pre-column (5 × 2.1 mmID, particle size 1.7μm) at 40°C, using H2O + 0.1% HCOOH in H2O (A) and CH3CN + 0.1% HCOOH (B) as mobile phase. ESI was applied in positive mode. The response factors, calculated on the basis of the internal standard peak area, were plotted over time. Response factor versus time profiles were fitted with Prism (GraphPad Software, Inc., USA) to estimate compounds half-life (t½) in mouse plasma.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!